Celldex Therapeutics (CLDX) Assets Average (2011 - 2026)
Celldex Therapeutics (CLDX) posted quarterly Assets Average of $547.1 million for Q1 2026, down 28.57% year-over-year from $765.9 million in Q1 2025, and down 11.14% quarter-over-quarter from $615.7 million in Q4 2025.
Celldex Therapeutics (CLDX) Assets Average (2011 - 2026) Analysis & Trends
Celldex Therapeutics' Assets Average history runs 16 years deep, the most recent figure standing at $547.1 million for Q1 2026.
- In Q1 2026, Assets Average fell 28.57% year-over-year to $547.1 million; the TTM figure through Mar 2026 stood at $547.1 million (down 28.57% YoY), while the FY2025 annual figure was $687.7 million, up 9.33% from the prior year.
- Assets Average for Q1 2026 stood at $547.1 million, down from $615.7 million in the prior quarter.
- The five-year high for Assets Average was $857.2 million in Q2 2024, with the low at $289.8 million in Q3 2023.
- The 5-year median for Assets Average is $547.1 million (2026), against an average of $552.3 million.
- The sharpest annual moves came in 2024 and 2026: Assets Average jumped 187.93% in 2024, then fell 28.57% in 2026.
- Celldex Therapeutics' Assets Average stood at $361.0 million in 2022, then climbed by 3.31% to $372.9 million in 2023, then soared by 116.59% to $807.8 million in 2024, then decreased by 23.78% to $615.7 million in 2025, then slipped by 11.14% to $547.1 million in 2026.
- Business Quant data shows CLDX's Assets Average at $547.1 million in Q1 2026, $615.7 million in Q4 2025, and $670.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Celldex Therapeutics | 3.29 Bn | 2.58 Bn | -2.57 Mn | 646.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 646.80 Mn |
| Mar 31, 2026 | 547.12 Mn |
| Dec 31, 2025 | 615.71 Mn |
| Sep 30, 2025 | 670.42 Mn |
| Jun 30, 2025 | 715.94 Mn |
| Mar 31, 2025 | 765.91 Mn |
| Dec 31, 2024 | 807.76 Mn |
| Sep 30, 2024 | 834.38 Mn |
| Jun 30, 2024 | 857.22 Mn |
| Mar 31, 2024 | 667.24 Mn |
| Dec 31, 2023 | 372.94 Mn |
| Sep 30, 2023 | 289.78 Mn |
| Jun 30, 2023 | 311.92 Mn |
| Mar 31, 2023 | 338.63 Mn |
| Dec 31, 2022 | 360.98 Mn |
| Sep 30, 2022 | 386.09 Mn |
| Jun 30, 2022 | 413.50 Mn |
| Mar 31, 2022 | 434.35 Mn |
| Dec 31, 2021 | 452.43 Mn |
| Sep 30, 2021 | 332.38 Mn |